C4 Therapeutics, Inc. (CCCC)

From the record

C4 Therapeutics, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

C4 Therapeutics, Inc.'s 5 filed years say what it did: revenue went from $46 million in fiscal 2021 to $36 million in fiscal 2025, down 5.9% a year; it rose in 2 of 4 years; the deepest fall was 55% from fiscal 2021 to fiscal 2023; net income was positive in 0 of 5 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, C4 Therapeutics, Inc. lost about 41 cents for every dollar of shareholders' money. Leverage: it owed about 29 cents per dollar of assets, and net share issuance: its share count grew 19.5% over the year (the filed statements).

From the record

C4 Therapeutics, Inc.'s standing among 102 graded names in its industry family: revenue of $36 million in fiscal 2025 ranks in the top 47% by size; a net margin of -292.1% ranks in the bottom 50%; revenue growth of 4.9% a year over the last 3 filed years ranks in the top 49% (its annual reports).

From the record

C4 Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Hirsch, Andrew (President & CEO, as filed), filing under that title since 2020-10-05, 6.1 years (top 33% of its family); the 15 officers and directors filing in the last fifteen months have been on the record a median of 3.3 years (bottom 17%); 10 officer or director changes were reported on Form 8-K since 2023-11-13, against the 15 people in charge now (bottom 33%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

C4 Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $78 million against no long-term debt tagged leaves 21.7% of its assets as net cash, bottom 44% of its family; cash from operations less capital spending is -276.2% of revenue (bottom 46%); research spending of 290% of revenue (top 40%) (its annual report).

From the record

C4 Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 4.9% a year over the last three filed years against -5.9% over all 5, speeding up (top 16% of its family); the newest year grew 1% (bottom 36%); research spending grew -4% a year (bottom 37%); capital spending grew -52% a year (bottom 29%) (its annual reports). C4 Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

C4 Therapeutics, Inc.'s newest year against its own record: revenue of $36 million in fiscal 2025 came in 5.6% below the $38 million its prior three years' pace pointed to (bottom 36% of its family); net income of $105 million against a prior three-year average of $122 million (top 50%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 41%) (its annual reports).